Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
Newsroom
Recent News
Archives
E-Alerts
Press Kit
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
E-Alerts
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Email:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

Newsroom

Nutra Pharma Corporation Will be Presenting at The Wall Street Analyst Forum
February 02, 2005

Nutra Pharma Corp., a biotechnology holding company that owns rights to intellectual property related to the development of drugs for HIV and Multiple Sclerosis, has today announced that its management will make a presentation to analysts and portfolio managers at The Wall Street Analyst Forum's 16th Annual NYC Analyst Conference on Monday, February 28th at 11:40 am eastern time.

Approximately 65 public companies will be presenting at the Conference being held at the Roosevelt Hotel on Madison Avenue at East 45th Street in New York City. Analysts and portfolio managers who wish to attend the presentation should contact The Wall Street Analyst Forum at (802)253-7596 to request additional information.

Investors may access an Internet webcast of the presentation at: http://www.vcall.com/CEPage.asp?ID=90209

"We are excited at the opportunity to present the Company's business model at The Wall Street Analysts Forum," stated Rik Deitsch, Nutra Pharma's Chairman and Chief Executive Officer. "We will endeavor to communicate Nutra Pharma's current situation as well as the Company's 2005 agenda," he concluded.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The upcoming presentation at the Wall Street Analyst Forum's 16th Annual NYC Analyst Conference should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


 
Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.
 

 

 
Recent News
 
June 21, 2017
Nutra Pharma Announcing Launch of Luxury Feet


June 07, 2017
Nutra Pharma Featured on Univision's Spanish-Language News Show: Primer Impacto


May 31, 2017
Nutra Pharma Announces Collaboration with the University of Maryland Bioprocess Scale-Up Facility in Preparation of Material for Phase II Studies


 
 
Announcements
Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
 
 
Facebook   Twitter
 
NPC
Privacy Policy Code of Ethics